By Market Intelligence Team

OPEN MINDS, The Behavioral Health & Social Service Industry Analyst Industry News On March 26, 2001, Forest Laboratories Inc. announced that it submitted a new drug application with the US Food and Drug Administration (FDA) to market Escitalopram for the treatment of depression. Ken Goodman, president and chief operating officer of Forest Laboratories, says the new antidepressant drug is more potent than the company's drug, Celexa. He says Escitalopram has good potency and few side effects. This drug is the single isomer version of Celexa and is a more selective . . .
Restricted Content

You must be a member to view this resource.

Log in | Sign up or learn more about membership options
OPEN MINDS, The Behavioral Health & Social Service Industry Analyst Industry News On March 26, 2001, Forest Laboratories Inc. announced that it submitted a new drug application with the US Food and Drug Administration (FDA) to market Escitalopram for the treatment of depression. Ken Goodman, president and chief operating officer of Forest Laboratories, says the new antidepressant drug is more potent than the company's drug, Celexa. He says Escitalopram has good potency and few side effects. This drug is the single isomer version of Celexa and is a more selective . . .
Restricted Content

You must be a member to view this resource.

Log in | Sign up or learn more about membership options

Login to access The OPEN MINDS Circle Library. Not a member? Create your free account now!